MDMA-Study for Traumatic Brain Injury and FACTS About Recreational Use.
As a “club drug” popular at music events, raves, and concerts, some have reported using during filming of movies, MDMA first came onto the drug scene in the late 70s and early 80s. Molly is another name for ecstasy (X), a synthetic amphetamine. It reduces anxiety and stimulates the mind. MDMA may have a reputation as a party drug, but it can actually be quite dangerous.
Facts About MDMA
Among the hallucinogens, MDMA is considered a stimulant. Involuntary teeth clenching, blurred vision, nausea, increased heart rate, and rapid breathing are common side effects. A tablet with a color design, a logo, or a cartoon character is usually what it looks like, but it can also be powder, liquid, or capsule-shaped, and it has a bitter taste.
MDMA is not always present in “ecstasy” tablets, according to some studies. As an alternative, many were a mixture of fake cocaine (aka “bath salts”) or other chemicals such as cocaine, meth, LSD, or ketamine. As a result, MDMA pills are especially dangerous since users are often unaware of what they are taking.
Effects of MDMA on the Brain
Any MDMA pill has unidentified ingredients until it is tested. Therefore, the drug may interact with any other substances the user is currently taking, such as alcohol, stimulants, or depressants. The interaction can damage the brain, heart, and other organs in the body.
Some effects of MDMA include:
- Mental stimulation
- Loss of inhibitions
- Increased sense of well-being
- Increased sensory perception
- More energy
These effects are the reasons why people use MDMA, but there are many negative side effects, too, including:
- Chills or hot flashes
- Nausea or vomiting
- Clenching teeth
- Loss of appetite
- Muscle cramps
- Disorganized thinking
The use of MDMA isn’t harmless – adverse cardiovascular effects, hyperthermia (high body temperature), risky behavior, and impaired mental abilities occur when it is consumed.
MDMA can cause sleeping problems, confusion, dilated pupils, and chills or sweats. Swinging moods are also common, as are overly sensitive emotions. Excessive energy is another sign.
Ecstasy overdose symptoms can include high blood pressure, loss of consciousness, lightheadedness or fainting, panic attacks, and even seizures.
Can I Get Addicted To MDMA?
The mental effects of MDMA may be habit-forming, yet NIDA hasn’t clearly demonstrated that a user may become addicted to it physically. In addition, long-term MDMA usage can be dangerous. Since MDMA acts on the same neurotransmitters as other addicting chemicals, it is possible that it’ll be addictive.
MDMA withdrawal symptoms can make a person feel somber, lethargic, and anxious. They may seek the drug out again in order to reestablish their pleasure and high.
MDMA-Study for Traumatic Brain Injury.
Because MDMA tablets, drinks, and substances may not contain genuine ecstasy and instead contain other street substances, it is critical to stop using it. Someone who uses MDMA, which is methamphetamine, for example, may become addicted to it.
Treating MDMA Use
The effects of MDMA, like every drug, are detrimental to the brain and body. If you or a treasured one is exploiting MDMA, there are alternative treatments.
A $1.5M donation is given to MDMA study for concussions MDMA for concussions will be studied by Wesana Health in a MAPS study. Wesana Health Holdings Inc. announced on September 14 its commitment to fund $1.5 million to assess the effectiveness of MDMA-assisted therapy for treating traumatic brain injury (TBI) as part of the Multidisciplinary Association for Psychedelic Studies (MAPS).
Wesana Company offers psychedelic-assisted therapy with seriousness, compassion, and ethics. Our beliefs are that Daniel’s and Wesana’s work is in line with MAPS’ values, mission, ethics, and expertise, and that we can create a massively underserved segment of the TBI community by partnering with him. Clinical evidence collected from MAPS-sponsored clinical trials suggests that MDMA-assisted treatment offers a potential treatment alternative for TBI.
A review of data collected from MDMA-assisted clinical trials sponsored by MAPS indicates that the treatment of TBI with MDMA has promise. This is an important step toward finding effective treatments for MDMA-affected patients that could be helped by the drug,” said Rick Doblin, Ph.D., Executive Director of MAPS.
PTSD-assisted MDMA therapy has been a focus of MAPS in recent months. Two Phase 3 trials showed 88 percent of participants reduced their PTSD symptoms clinically significant.
It has been shown that MDMA improves cognitive function in mice with minimal TBI. Like PTSD, TBI can have a big impact on mental health. The research indicates that there is a disproportionate impact for minority groups.
There are estimated to be over 6.2 million people with chronic TBI-related disabilities, on top of the milder symptoms that still affect their daily lives. The number of Iraq and Afghanistan veterans who suffered a TBI was about 414,000.
MAPS’ years of working with regulators and researchers to navigate the rigorous and necessary FDA approval process for MDMA therapeutic use has put psychedelic-assisted therapy on the verge of national acceptance, according to Daniel Carcillo, CEO of Wesana Health. The millions of people struggling from PTSD may soon be able to get MDMA therapy, and we believe the millions who suffer from TBI may also benefit from the treatment.”
This collaboration between MAPS and Wesana will speed up MAPS PBC’s research timelines and offer additional support for future research, awareness, education, and universal access to MDMA-assisted therapy treatments.
The following five goals were outlined by Wesana:
• The process of developing psychedelic assisted TBI treatment programs will be improved along with Wesana’s timelines and paths to market for its treatments as you gain expertise and information.
• Seek an exclusive license to use MDMA in the treatment of TBI
• The organizational revenue sharing agreements should be evaluated for their viability
• A program to benefit patient access should be adapted from MAPS’ equity research projects
• With additional capital, MAPS PBC will fund associated research
MAPS advances psychedelic research beyond MDMA
Research on psychedelics with potential for medical use is being carried out by MAPS. The state of Michigan has awarded MAPS $12,979,050 for a study of cannabis and post-traumatic stress disorder (PTSD).
The new study is much needed by the community, says Dr. Sue Sisley, President of the Scottsdale Research Institute, and a long-time cannabis researcher.
The grant is funded by the state’s recreational weed tax and comes from Michigan’s Veteran Marijuana Research Grant Program for 2021. This study examines whether medical weed is effective in treating the medical conditions of veterans of the United States armed forces, as well as in reducing veteran suicides.
In the words of Berra Yazar-Klosinki, PhD, the Chief Science Officer of MAPS Public Benefit Corporation, the first trial was a great success, and the Michigan grant makes it the second clinical trial in which medical cannabis will be given to veterans.
MAPS’ MDMA research can now move forward as well thanks to Wesana Health’s commitment.